NCT05398926View on ClinicalTrials.gov

Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly

PHASE4CompletedINTERVENTIONAL

Enrollment

400

Participants

Timeline

Start Date

December 6, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

July 30, 2022

Conditions

COVID-19

Interventions

BIOLOGICAL

COVID-19 Vaccine (Vero cell), Inactivated

The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.600SU inactivated SARS-CoV-2 CZ strain virus in 0.5 mL of aluminium hydroxide solution per injection.

Trial Locations (1)

677600

Yongde Center for Diseases Control and Prevention, Lincang

All Listed Sponsors

lead

Sinovac Life Sciences Co., Ltd.

INDUSTRY

NCT05398926 - Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly | Biotech Hunter | Biotech Hunter